Lauri M. Burroughs, MD

She is conducting several clinical trials evaluating reduced intensity or nonmyelobaltive conditioning followed by transplant for patients with nonmalignant disorders.  One of the clinical trial is evaluating whether the addition of the T cell depleting agent Campath can decrease the incidence of graft versus host disease (GVHD) and improve donor chimerism following hematopoietic cell transplantation. In addition, in order to increase the number of patients with primary immunodeficiencies and other rare nonmalignant inherited diseases who may benefit from a transplant, Dr. Burroughs developed a clinical trial for patients who do not have an HLA-matched related or unrelated donor. Patients receiving a nonmyeloablative conditioning regimen will receive cyclophosphamide before and after hematopoietic cell transplantation followed by HLA-haploidentical grafts to remove alloreactive T cells with the goal of improving engraftment and decreasing GVHD.  Finally, Dr. Burroughs is exploring a reduced intensity regimen that incorporates Treosulfan a Busulfan analog into the preparative regimen which in several clinical trials has been shown to be associated with significantly reduced toxicity and as a result decreased transplant related mortality following transplant.  In collaboration with the Immunology group at Seattle Children's, Dr. Burroughs is evaluating how the immune system reconstitutes following transplant.